Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Mortality from pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide and
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …

Purpose: Gemcitabine is most commonly used for pancreatic cancer. However, the
molecular features and mechanisms of the frequently occurring resistance remain unclear …

Background The epigenetic mechanisms involved in the progression of pancreatic ductal
adenocarcinoma (PDAC) remain largely unexplored. This study aimed to identify key …

Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be
second only to lung cancer. We have seen tremendous advances in therapies for lung …

Pancreatic ductal adenocarcinoma is a highly malignant gastrointestinal tumor. Molecular
targeting therapy for pancreatic cancer is still limited. High expressed Galectin-3 in …

Purpose Oncogenic KRAS mutations are found in over 90% of pancreatic ductal
adenocarcinomas (PDACs). As yet, however, no effective therapies are available for KRAS …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due
to late detection and highly metastatic characteristics. PDAC cells vary in their tumorigenic …

Gemcitabine (GEM) is the first-line medication for pancreatic ductal adenocarcinoma
(PDAC). However, over some treatment cycles, GEM sensitivity declines and …

Epigenetic modifications could drive some of the molecular events implicated in
proliferation, drug resistance and metastasis of pancreatic ductal adenocarcinoma (PDAC) …